BioNTech today announced in a press release that the Pfizer-BioNTech vaccine is 100% effective for the 12-15 age group, INTERFAX reported.
The drug developed by the German company BioNTech and the American Pfizer turned out to be the most effective for adolescents 12-15 years old. BioNTech’s press release states:
Pfizer and BioNTech today announced that Pfizer-BioNTech’s COVID-19 vaccine has demonstrated 100% efficacy and an active immune response in a third phase of trials in adolescents aged 12 to 15 years with no prior evidence of SARS-CoV-2 infection ( from test participants).
At the same time, it is noted that all children tolerated the vaccine well. Pfizer CEO Albert Burla says:
We share an understanding of the urgent need for greater approval of our vaccine for use by younger populations and are encouraged by the data from clinical trials in adolescents aged 12 to 15 years.
Burla said the companies are counting on regulatory approval to begin administering the vaccine to adolescents, and it would be good to start vaccinating children of this age before the start of the next school year:
We plan to submit this data to the FDA in the coming weeks as a proposed amendment to our emergency drug authorization, as well as to other regulatory agencies around the world.
The trial in the United States involved 2,260 adolescents, ranging in age from 12 to 15 years. Trials are currently underway in other age groups, the company says. Children aged 5 to 11 started getting immunized last week. The next one will start testing in the age group 2-5 years.